Braizon Therapeutics is a bio-venture firm originating from the University of Tokyo and Tokyo Medical and Dental University.
Braizon Therapeutics has raised $9.5M in total funding. The most recent round was Series B. The last funding was announced in July 2021.
Braizon Therapeutics's investors include SMBC Venture Capital, Fast Track Initiative, Inc., UTokyo Innovation Platform.
Braizon Therapeutics is headquartered in Hongo, Japan.
Braizon Therapeutics is a bio-venture firm originating from the University of Tokyo and Tokyo Medical and Dental University.
Braizon Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Braizon Therapeutics — Funding & Investors." VCBacked, July 9, 2021, https://www.vcbacked.co/company/braizon-therapeutics. Accessed September 29, 2026.
VCBacked. (2021). Braizon Therapeutics — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/braizon-therapeutics
{{cite web |title=Braizon Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/braizon-therapeutics |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated